Michael King
Stock Analyst at EF Hutton
(0.79)
# 3,950
Out of 5,008 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $18.43 | +3,426.28% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $5.05 | +23,250.50% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.55 | +141.76% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.85 | +1,634.42% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $2.43 | +2,718.93% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $16.69 | +1,098.32% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.93 | +330.05% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $583.24 | +47.80% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $39.63 | -39.44% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $4.25 | +3,805.88% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $12.03 | +249.13% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $459.58 | -33.85% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $20.44 | +467.51% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.61 | +185.32% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $39.50 | -39.24% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $4.52 | +265,386.73% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $29.87 | +54.00% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $40.87 | +134.89% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.82 | +4,277.96% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $15.44 | +100.78% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $797.35 | -95.49% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $18.43
Upside: +3,426.28%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $5.05
Upside: +23,250.50%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.55
Upside: +141.76%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.85
Upside: +1,634.42%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $2.43
Upside: +2,718.93%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $16.69
Upside: +1,098.32%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.93
Upside: +330.05%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $583.24
Upside: +47.80%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $39.63
Upside: -39.44%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.25
Upside: +3,805.88%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $12.03
Upside: +249.13%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $459.58
Upside: -33.85%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $20.44
Upside: +467.51%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $3.61
Upside: +185.32%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $39.50
Upside: -39.24%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $4.52
Upside: +265,386.73%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $29.87
Upside: +54.00%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $40.87
Upside: +134.89%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.82
Upside: +4,277.96%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $15.44
Upside: +100.78%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $797.35
Upside: -95.49%